Correction to "Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study"
Cancer. 2025 Dec 15;131(24):e70188.
doi: 10.1002/cncr.70188.